{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:03:11Z","timestamp":1791414191815,"version":"4.3.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T00:00:00Z","timestamp":1590278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T00:00:00Z","timestamp":1590278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p><jats:italic>Mycobacterium fortuitum complex<\/jats:italic> is a group of rapidly growing nontuberculous mycobacteria (NTM) associated with skin and soft-tissue infections after surgery or trauma. Treatment of NTM is challenging, due to resistance to multiple antimycobacterial agents. Bedaquiline is a diarylquinoline that inhibits mycobacterial ATP-synthase. The drug has recently been approved for the treatment of multidrug-resistant tuberculosis and evidence of its in vitro efficacy against NTM, including <jats:italic>Mycobacterium fortuitum complex<\/jats:italic>, has been published.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 20-year-old Caucasian woman with chronic skin and soft tissue infection in the lower leg following a traffic accident in Vietnam underwent a tedious journey of healthcare visits, hospital admissions, empiric antimicrobial treatments, surgical debridement and plastic reconstruction before definite diagnosis of <jats:italic>Mycobacterium fortuitum complex<\/jats:italic>-infection was established by culture from a tissue biopsy and targeted antimycobacterial therapy was administered. Histopathological examination revealed granulomatous purulent inflammation, which strongly supported the diagnosis. Genotypic identification was performed and broth microdilution for susceptibility testing showed macrolide resistance. Five weeks of induction treatment with intravenous amikacin, imipenem \/ cilastin, and oral levofloxacin was administered, followed by all-oral treatment with bedaquiline combined with levofloxacin for four months, which was well-tolerated and led to persistent healing with scars but without signs of residual infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Bedaquiline is a promising novel agent for NTM treatment, although clinical data are limited and trials evaluating efficacy, safety, and resistance of bedaquiline are required. To our knowledge, this is the first reported case of successful in vivo use of bedaquiline for a skin and soft tissue infection caused by <jats:italic>Mycobacterium fortuitum complex<\/jats:italic>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-020-05075-7","type":"journal-article","created":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T10:02:33Z","timestamp":1590314553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Successful bedaquiline-containing antimycobacterial treatment in post-traumatic skin and soft-tissue infection by Mycobacterium fortuitum complex: a case report"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6614-6051","authenticated-orcid":false,"given":"Johanna","family":"Erber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Weidlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Tschaikowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Rothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland M.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3875-5367","authenticated-orcid":false,"given":"Christoph D.","family":"Spinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,24]]},"reference":[{"issue":"4","key":"5075_CR1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","volume":"175","author":"DE Griffith","year":"2007","unstructured":"Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367\u2013416.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"5075_CR2","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1128\/CMR.15.4.716-746.2002","volume":"15","author":"BA Brown-Elliott","year":"2002","unstructured":"Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev. 2002;15(4):716\u201346.","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"5075_CR3","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1128\/AEM.65.6.2492-2496.1999","volume":"65","author":"TC Covert","year":"1999","unstructured":"Covert TC, Rodgers MR, Reyes AL, Stelma GN Jr. Occurrence of nontuberculous mycobacteria in environmental samples. Appl Environ Microbiol. 1999;65(6):2492\u20136.","journal-title":"Appl Environ Microbiol"},{"key":"5075_CR4","doi-asserted-by":"crossref","unstructured":"Brown-Elliott BA, Philley JV. Rapidly Growing Mycobacteria. Microbiol Spectrum. 2017;5(1):TNMI7-0027-2016.","DOI":"10.1128\/microbiolspec.TNMI7-0027-2016"},{"issue":"1","key":"5075_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12879-018-3043-7","volume":"18","author":"MJ Donohue","year":"2018","unstructured":"Donohue MJ. Increasing nontuberculous mycobacteria reporting rates and species diversity identified in clinical laboratory reports. BMC Infect Dis. 2018;18(1):163.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"5075_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.mayocp.2012.06.029","volume":"88","author":"AB Wentworth","year":"2013","unstructured":"Wentworth AB, Drage LA, Wengenack NL, Wilson JW, Lohse CM. Increased incidence of cutaneous nontuberculous mycobacterial infection, 1980 to 2009: a population-based study. Mayo Clin Proc. 2013;88(1):38\u201345.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"5075_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1086\/313589","volume":"30","author":"P Chetchotisakd","year":"2000","unstructured":"Chetchotisakd P, Mootsikapun P, Anunnatsiri S, Jirarattanapochai K, Choonhakarn C, Chaiprasert A, Ubol PN, Wheat LJ, Davis TE. Disseminated infection due to rapidly growing mycobacteria in immunocompetent hosts presenting with chronic lymphadenopathy: a previously unrecognized clinical entity. Clin Infect Dis. 2000;30(1):29\u201334.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"5075_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1055\/s-0033-1333569","volume":"34","author":"J van Ingen","year":"2013","unstructured":"van Ingen J. Diagnosis of nontuberculous mycobacterial infections. Semin Respir Crit Care Med. 2013;34(1):103\u20139.","journal-title":"Semin Respir Crit Care Med"},{"issue":"5","key":"5075_CR9","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1128\/JCM.44.5.1769-1775.2006","volume":"44","author":"E Richter","year":"2006","unstructured":"Richter E, Rusch-Gerdes S, Hillemann D. Evaluation of the GenoType Mycobacterium assay for identification of mycobacterial species from cultures. J Clin Microbiol. 2006;44(5):1769\u201375.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"5075_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11908-018-0611-3","volume":"20","author":"EA Misch","year":"2018","unstructured":"Misch EA, Saddler C, Davis JM. Skin and soft tissue infections due to Nontuberculous mycobacteria. Curr Infect Dis Rep. 2018;20(4):6.","journal-title":"Curr Infect Dis Rep"},{"key":"5075_CR11","doi-asserted-by":"crossref","unstructured":"Yu X, Gao X, Li C, Luo J, Wen S, Zhang T, Ma Y, Dong L, Wang F, Huang H. In Vitro Activities of Bedaquiline and Delamanid against Nontuberculous Mycobacteria Isolated in Beijing, China. Antimicrob Agents Chemother. 2019;63(8):00031\u201319.","DOI":"10.1128\/AAC.00031-19"},{"key":"5075_CR12","first-page":"4902941","volume":"2018","author":"Y Shen","year":"2018","unstructured":"Shen Y, Wang X, Jin J, Wu J, Zhang X, Chen J, Zhang W. In vitro susceptibility of Mycobacterium abscessus and Mycobacterium fortuitum isolates to 30 antibiotics. Biomed Res Int. 2018;2018:4902941.","journal-title":"Biomed Res Int"},{"key":"5075_CR13","unstructured":"Woods GL, Brown-Elliott BA, Conville PS, Desmond EP, Hall GS, Lin G, Pfyffer GE, Ridderhof JC, Siddiqi SH, Wallace RJ, Jr. et al: CLSI Standards: Guidelines for Health Care Excellence. In: Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes. edn. Edited by nd. Wayne: Clinical and Laboratory Standards Institute Copyright (c)2011 Clinical and Laboratory Standards Institute; 2011."},{"issue":"2","key":"5075_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/jac\/dkh523","volume":"55","author":"KA Nash","year":"2005","unstructured":"Nash KA, Zhang Y, Brown-Elliott BA, Wallace RJ Jr. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. J Antimicrob Chemother. 2005;55(2):170\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"5075_CR15","doi-asserted-by":"crossref","unstructured":"Pang Y, Zheng H, Tan Y, Song Y, Zhao Y. In Vitro Activity of Bedaquiline against Nontuberculous Mycobacteria in China. Antimicrob Agents Chemother. 2017:61(5):02627\u201316.","DOI":"10.1128\/AAC.02627-16"},{"issue":"1","key":"5075_CR16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ccm.2014.10.004","volume":"36","author":"SH Kasperbauer","year":"2015","unstructured":"Kasperbauer SH, De Groote MA. The treatment of rapidly growing mycobacterial infections. Clin Chest Med. 2015;36(1):67\u201378.","journal-title":"Clin Chest Med"},{"key":"5075_CR17","doi-asserted-by":"crossref","unstructured":"Brown-Elliott BA, Woods GL. Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria. J Clin Microbiol. 2019:57(10):00834\u201319.","DOI":"10.1128\/JCM.00834-19"},{"issue":"3","key":"5075_CR18","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1128\/AAC.01611-09","volume":"54","author":"E Huitric","year":"2010","unstructured":"Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S, Andersson DI. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother. 2010;54(3):1022\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"5075_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/2229-516X.112228","volume":"3","author":"R Mahajan","year":"2013","unstructured":"Mahajan R. Bedaquiline: first FDA-approved tuberculosis drug in 40 years. Int J Appl Basic Med Res. 2013;3(1):1\u20132.","journal-title":"Int J Appl Basic Med Res"},{"issue":"8","key":"5075_CR20","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1099\/jmm.0.000537","volume":"66","author":"DA Aguilar-Ayala","year":"2017","unstructured":"Aguilar-Ayala DA, Cnockaert M, Andre E, Andries K, Gonzalez YMJA, Vandamme P, Palomino JC, Martin A. In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria. J Med Microbiol. 2017;66(8):1140\u20133.","journal-title":"J Med Microbiol"},{"issue":"2","key":"5075_CR21","doi-asserted-by":"publisher","first-page":"e01919","DOI":"10.1128\/AAC.01919-18","volume":"63","author":"Barbara A. Brown-Elliott","year":"2018","unstructured":"Brown-Elliott BA, Wallace RJ Jr. In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium abscessus Complex. Antimicrob Agents Chemother. 2019;63(2):01919\u201318.","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"4","key":"5075_CR22","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1093\/jac\/dky526","volume":"74","author":"MM Ruth","year":"2019","unstructured":"Ruth MM, Sangen JJN, Remmers K, Pennings LJ, Svensson E, Aarnoutse RE, Zweijpfenning SMH, Hoefsloot W, Kuipers S, Magis-Escurra C, et al. A bedaquiline\/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria. J Antimicrob Chemother. 2019;74(4):935\u201343.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"5075_CR23","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1378\/chest.14-2764","volume":"148","author":"JV Philley","year":"2015","unstructured":"Philley JV, Wallace RJ Jr, Benwill JL, Taskar V, Brown-Elliott BA, Thakkar F, Aksamit TR, Griffith DE. Preliminary results of Bedaquiline as salvage therapy for patients with Nontuberculous mycobacterial lung disease. Chest. 2015;148(2):499\u2013506.","journal-title":"Chest"},{"issue":"4","key":"5075_CR24","first-page":"1083","volume":"151","author":"C Jagannath","year":"1995","unstructured":"Jagannath C, Reddy MV, Kailasam S, O'Sullivan JF, Gangadharam PR. Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies. Am J Respir Crit Care Med. 1995;151(4):1083\u20136.","journal-title":"Am J Respir Crit Care Med"},{"key":"5075_CR25","unstructured":"Bedaquiline (Sirturo) for multidrug-resistant tuberculosis. Medical Lett Drugs Ther. 2013;55(1423):66\u20138."},{"issue":"3","key":"5075_CR26","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1093\/infdis\/152.3.500","volume":"152","author":"RJ Wallace Jr","year":"1985","unstructured":"Wallace RJ Jr, Swenson JM, Silcox VA, Bullen MG. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis. 1985;152(3):500\u201314.","journal-title":"J Infect Dis"},{"issue":"11","key":"5075_CR27","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1086\/420742","volume":"38","author":"CA Peloquin","year":"2004","unstructured":"Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, Iseman MD, Cook JL, Curran-Everett D. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis. 2004;38(11):1538\u201344.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"5075_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40360-019-0302-1","volume":"20","author":"ML Aznar","year":"2019","unstructured":"Aznar ML, Marras TK, Elshal AS, Mehrabi M, Brode SK. Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada. BMC Pharmacol & Toxicol. 2019;20(1):37.","journal-title":"BMC Pharmacol & Toxicol"},{"issue":"Suppl A","key":"5075_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/jac\/13.suppl_A.9","volume":"13","author":"G Kahlmeter","year":"1984","unstructured":"Kahlmeter G, Dahlager JI. Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother. 1984;13(Suppl A):9\u201322.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"5075_CR30","doi-asserted-by":"publisher","first-page":"645","DOI":"10.5588\/ijtld.18.0622","volume":"23","author":"C Lange","year":"2019","unstructured":"Lange C, Aarnoutse RE, Alffenaar JWC, Bothamley G, Brinkmann F, Costa J, Chesov D, van Crevel R, Dedicoat M, Dominguez J, et al. Management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23(6):645\u201362.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"12","key":"5075_CR31","doi-asserted-by":"publisher","first-page":"6324","DOI":"10.1128\/AAC.01505-12","volume":"56","author":"J van Ingen","year":"2012","unstructured":"van Ingen J, Totten SE, Helstrom NK, Heifets LB, Boeree MJ, Daley CL. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother. 2012;56(12):6324\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"5075_CR32","doi-asserted-by":"crossref","unstructured":"Luo J, Yu X, Jiang G, Fu Y, Huo F, Ma Y, Wang F, Shang Y, Liang Q, Xue Y, et al. In Vitro Activity of Clofazimine against Nontuberculous Mycobacteria Isolated in Beijing, China. Antimicrob Agents Chemother. 2018;62(7):00072\u201318.","DOI":"10.1128\/AAC.00072-18"},{"key":"5075_CR33","doi-asserted-by":"crossref","unstructured":"Kim DH, Jhun BW, Moon SM, Kim SY, Jeon K, Kwon OJ, Huh HJ, Lee NY, Shin SJ, Daley CL, et al. In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates. Antimicrob Agents Chemother. 2019;63(8):00665\u201319.","DOI":"10.1128\/AAC.00665-19"},{"issue":"2","key":"5075_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ijantimicag.2009.09.023","volume":"35","author":"J van Ingen","year":"2010","unstructured":"van Ingen J, van der Laan T, Dekhuijzen R, Boeree M, van Soolingen D. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in the Netherlands. Int J Antimicrob Agents. 2010;35(2):169\u201373.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"5075_CR35","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ijantimicag.2009.12.008","volume":"35","author":"GH Shen","year":"2010","unstructured":"Shen GH, Wu BD, Hu ST, Lin CF, Wu KM, Chen JH. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents. 2010;35(4):400\u20134.","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"5075_CR36","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1128\/AAC.00181-07","volume":"51","author":"E Huitric","year":"2007","unstructured":"Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother. 2007;51(11):4202\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5707","key":"5075_CR37","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1126\/science.1106753","volume":"307","author":"K Andries","year":"2005","unstructured":"Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307(5707):223\u20137.","journal-title":"Science"},{"issue":"6","key":"5075_CR38","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/infdis\/jit614","volume":"209","author":"I Lerat","year":"2014","unstructured":"Lerat I, Cambau E, Roth Dit Bettoni R, Gaillard JL, Jarlier V, Truffot C, Veziris N. In vivo evaluation of antibiotic activity against Mycobacterium abscessus. J Infect Dis. 2014;209(6):905\u201312.","journal-title":"J Infect Dis"},{"key":"5075_CR39","doi-asserted-by":"crossref","unstructured":"Dupont C, Viljoen A, Thomas S, Roquet-Baneres F, Herrmann JL, Pethe K, Kremer L. Bedaquiline Inhibits the ATP Synthase in Mycobacterium abscessus and Is Effective in Infected Zebrafish. Antimicrob Agents Chemother. 2017;61(11):01225\u201317.","DOI":"10.1128\/AAC.01225-17"},{"issue":"2","key":"5075_CR40","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1128\/JCM.02087-16","volume":"55","author":"DC Alexander","year":"2017","unstructured":"Alexander DC, Vasireddy R, Vasireddy S, Philley JV, Brown-Elliott BA, Perry BJ, Griffith DE, Benwill JL, Cameron AD, Wallace RJ Jr. Emergence of mmpT5 variants during Bedaquiline treatment of Mycobacterium intracellulare lung disease. J Clin Microbiol. 2017;55(2):574\u201384.","journal-title":"J Clin Microbiol"},{"issue":"2","key":"5075_CR41","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1183\/13993003.01891-2015","volume":"47","author":"E Pontali","year":"2016","unstructured":"Pontali E, Sotgiu G, D'Ambrosio L, Centis R, Migliori GB. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J. 2016;47(2):394\u2013402.","journal-title":"Eur Respir J"},{"issue":"5","key":"5075_CR42","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1183\/13993003.01980-2015","volume":"47","author":"JM Lewis","year":"2016","unstructured":"Lewis JM, Hine P, Walker J, Khoo SH, Taegtmeyer M, Squire SB, Sloan DJ. First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB. Eur Respir J. 2016;47(5):1581\u20134.","journal-title":"Eur Respir J"},{"issue":"10","key":"5075_CR43","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Egizi E, Moreira J, Timm J, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893\u2013902.","journal-title":"N Engl J Med"},{"issue":"1","key":"5075_CR44","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ddr.21498","volume":"80","author":"Y Li","year":"2019","unstructured":"Li Y, Sun F, Zhang W. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: promising but challenging. Drug Dev Res. 2019;80(1):98\u2013105.","journal-title":"Drug Dev Res"},{"issue":"1","key":"5075_CR45","doi-asserted-by":"publisher","first-page":"1900118","DOI":"10.1183\/13993003.00118-2019","volume":"54","author":"Sanne M.H. Zweijpfenning","year":"2019","unstructured":"Zweijpfenning SMH, Schildkraut JA, Coolen JPM, Ruesen C, Koenraad E, Janssen A, Ruth MM, de Jong AS, Kuipers S, Aarnoutse RE, et al. Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease. Eur Respir J. 2019;54(1):00118\u20132019.","journal-title":"European Respiratory Journal"},{"issue":"10","key":"5075_CR46","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/cid\/cix992","volume":"66","author":"TVA Nguyen","year":"2018","unstructured":"Nguyen TVA, Anthony RM, Banuls AL, Nguyen TVA, Vu DH, Alffenaar JC. Bedaquiline resistance: its emergence, mechanism, and prevention. Clin Infect Dis. 2018;66(10):1625\u201330.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05075-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-05075-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05075-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,23]],"date-time":"2021-05-23T23:11:46Z","timestamp":1621811506000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05075-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,24]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5075"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05075-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,24]]},"assertion":[{"value":"12 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report as well as any accompanying images. A copy of the written consent form is available for review by the editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Christoph D. Spinner has received research grants from and served on advisory boards and speaker bureaus for Janssen-Cilag. All other authors declare no conflicts of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"365"}}